君实生物:抗IL-17A单抗治疗中重度斑块状银屑病的Ⅲ期临床研究达到主要研究终点

Core Viewpoint - Junshi Biosciences (688180.SH) announced positive results from a pivotal Phase III clinical trial for its product, a humanized anti-IL-17A monoclonal antibody (code: JS005), in treating moderate to severe plaque psoriasis, with both primary and key secondary endpoints showing statistical significance and clinical relevance [1] Group 1 - The clinical study was a multicenter, randomized, double-blind, parallel, placebo-controlled trial (study number: JS005-005-III-PsO) [1] - The company plans to submit a marketing authorization application for the product to regulatory authorities in the near future [1]